MedPath
Found 2 clinical trials|View Analysis
Sort by:

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Phase 2
Completed
Conditions
NSCLC
Interventions
First Posted Date
2023-10-23
Last Posted Date
2024-10-14
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
1
Registration Number
NCT06094296
Locations
🇺🇸

Local Institution - 0058, Boise, Idaho, United States

🇺🇸

Local Institution - 0044, Clermont, Florida, United States

🇺🇸

Local Institution - 0049, Houston, Texas, United States

and more 5 locations

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

Phase 1
Terminated
Conditions
Advanced Solid Tumor
Interventions
First Posted Date
2020-04-16
Last Posted Date
2024-10-23
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
44
Registration Number
NCT04349267
Locations
🇺🇸

Local Institution - 0001, Germantown, Tennessee, United States

🇺🇸

Local Institution - 0028, Sioux Falls, South Dakota, United States

🇨🇦

Local Institution - 0013, Ottawa, Canada

and more 5 locations
© Copyright 2025. All Rights Reserved by MedPath